Alaeddine SAIDI

MD medical oncology,
إستشاري طب الأورام السرطانية بالمستشفى الجامعي تلمسان وأستاذ بكلية الطب بجامعة تلمسان الجزائر

[Gaia Griguolo @GaiaGriguolo]

In the real world 🇮🇹 PALMARES2 trial, continuation of CDK4/6i+ET beyond progressive disease resulted in additional 10.5 mos in median rwPFS

Loco regional tx was associated with better rwPFS

@OncoAlert #asco26

[Novi Yanti Sari @slumberbell]

Just published in JACC @JACCJournals!🫀

Acute HF care is evolving:
📍Rapid diagnosis
📍Early decongestion
📍Timely GDMT initiation
📍Structured follow-up
📍Focus on long-term outcomes, not just symptom relief

Grateful to have contributed to this international collaboration & learned so much from the exceptional experts involved in this work. Congratulations to @Jolie_Bruno_ and @AlexMebazaa for the leadership & to all co-authors on this important publication🫀

Read the full paper🔗: https://t.co/408QmNOznr

#HeartFailure #AcuteHeartFailure #JACC @jozinetm @BiykemB @GianluSava @pmyhre

[Luca Arecco, MD @Lucarecco]

Ahead of #ASCO26, I selected some less high-profile but, in my opinion, really interesting breast cancer abstracts focused on #YoungPatients and #BRCA carriers (plus the 2 abstracts our group will present on these topics).

@matteolambe @E_de_Azambuja @OncoAlert @ASCO

[Advanced Prostate Cancer Consensus Conference @APCCC_Lugano]

Prevalence of symptomatic skeletal events (SSE) with reduced denosumab (Dmab) dose density (every 12 weeks versus every 4 weeks): A randomized phase III non-inferiority trial SAKK 96/12 REDUSE. Abstract 1004 to be presented at #ASCO26

https://t.co/ioQu0sQMYP

The SAKK 96/12 REDUSE trial demonstrated that denosumab administered every 12 weeks after an initial loading phase was non-inferior to standard every-4-week dosing in patients with 🦴bone-metastatic #BreastCancer or castration-resistant #ProstateCancer . Time to symptomatic skeletal events was comparable between schedules, while📉 reduced-frequency dosing resulted in lower rates of hypocalcemia and osteonecrosis of the jaw.

These findings support Q12W denosumab as a new standard of care, reducing toxicity, treatment burden, and healthcare costs without compromising efficacy.

@Silke_Gillessen @RothschildSacha

@OncoAlert
@AOmlin
@weoncologists

[Sung-Bae Kim @sbkim712]

🌟 Honored to speak at #ESMOBreast26 today on "Adjuvant CDK4/6 inhibitors: Could they replace chemo for intermediate-risk ER+ eBC?"

Outstanding educational session chaired by @SibylleLoibl, with C. Denkert, FC. Bidard & H. Parsons. 🎓

[Nieves Martinez Lago MD PhD @DraMartinezLago]

🎭 What defines a good oncologist?
🧩 7 key pillars:
💛 Patient-centered care
🤝 Relationships
🗣️ Authentic communication
🧠 Emotional intelligence
⚖️ Coping with burden
🌍 Embracing uncertainty
📚 Lifelong learning

✨ Beyond skills → humanistic oncology

🔗 https://t.co/LjI9XNWjP6
@OncoAlert

[Husam Abdel-Qadir @husam247]

1/ Very pleased to share our new State-of-the-Art Review in JACC: CardioOncology
In this review, we outline a practical framework for developing and evaluating risk prediction tools that are actually fit for cardio-oncology.
https://t.co/GpO8MPrEez

[Yakup Ergün @dr_yakupergun]

One of the most notable studies from #AACR26:

Daraxonrasib + gem/nab-paclitaxel shows a strong early signal in 1L mPDAC.

ORR 58%
DCR 90%
6-month PFS 84%!!

Things are finally moving in pancreatic cancer👇

https://t.co/ijyGOW6hmE

[Sociedad de Cardiología de Buenos Aires 🇦🇷 @Soca_BA]

https://t.co/NKUa0dhMxa

[Emre Yekedüz @yekeduz_emre]

NICE 2026 guideline for the diagnosis and management of #kidneycancer :
👉https://t.co/nEkyzojcrC

@OncoAlert #cancer #oncology @DrYukselUrun @urotoday @AUC3_Official

[Alaeddine SAIDI @Alaa_Onco]

@Cristiano Choukran Ronaldo 🙏

[Dr. Nina Niu Sanford @NiuSanford]

Someone suggested I make a table summarizing the video. Here it is!

[Meshal Alzakari | مشعل الزكري @docmeshal]

للمهتمين بالبحث العلمي 📚
ملف جدا جميل يشرح لك خطوة بخطوة طريقة نشر بحثك في مجلة ذات تصنيف عالي Q1 وطريقة العثور على المجلات المناسبة لبحثك
رابط الملف:
https://t.co/MnqIXZIpt5

[فرع وزارة الصحة بمنطقة المدينة المنورة @MOH_Madinah]

كيف نقلل خطر الإصابة من سرطان القولون والمستقيم؟

[Dr Sarah Sammons @drsarahsam]

In mBC, not all imaging changes mean your therapy has stopped working and switching too early is a real risk.

1/ RECIST 1.1 sets a clear bar for progression: ≥20% increase in the sum of target lesion diameters (with ≥5mm absolute increase), unequivocal progression of non-target lesions, or new lesions. Not every change on imaging meets this threshold.

2/ Three scenarios commonly and incorrectly flagged as progression: new asymptomatic sclerotic bone lesions, small mm asymptomatic changes in known lesions, and increased SUV on PET without corresponding size change. None of these, in isolation, trigger a therapy switch for me.

3/ Sclerotic bone lesions deserve particular attention. When effective therapy kills tumor cells in bone, the body lays down new bone matrix appearing dense and white on CT. This is a healing response, not new disease.

4/ The consequences of switching too early are real: loss of disease control from a working regimen, premature exhaustion of sequencing options.

5/ My approach: I integrate clinical symptoms, tumor markers, and serial scans together before making any decision to change therapy.

6/ Bottom line: confirm true progression before changing course. When in doubt, a short interval rescan is almost always preferable to an unnecessary switch.

#BreastCancer #MedOnc

[Oscar Tahuahua @OscarTahuahua]

Obesity is linked to at least 12 cancers.

Here’s part of the biology in @JAMA_current

Dysfunctional adipose tissue becomes a pro-tumor endocrine organ, driving insulin signaling, estrogen excess, chronic inflammation, and immune suppression.

In other words: obesity can help create the ecosystem cancer needs to grow.
https://t.co/o9OHokqMuJ @OncoAlert

[Advanced Prostate Cancer Consensus Conference @APCCC_Lugano]

Risks of thrombosis and hemorrhage in concurrent use of anticoagulants and potential interacting prostate cancer agents

https://t.co/Inu5taP3Zl

In a population-based retrospective study from Ontario and Alberta, Canada🇨🇦 (2012–2023), investigators evaluated whether androgen receptor pathway inhibitors interact with direct oral anticoagulants (DOACs) in patients with #ProstateCancer . Among 2,997 patients, concurrent use of enzalutamide or apalutamide with DOACs did not increase thrombosis risk, and abiraterone with DOACs did not increase bleeding risk🩸

Overall, combining these therapies showed no clinically meaningful impact on thrombotic or bleeding outcomes.

@TzufeiWang
@Dominick_Bosse
@pietro_ravani
@Msood99M
@MarcCarrier1

@OncoAlert
@silkegillessen
@AOmlin
@weoncologists
@JournalCancer

[Yakup Ergün @dr_yakupergun]

Stage 1 TNBC treatment algorithm

From Dr. David Cescon’s presentation at #ESMO24 👇

[MV Chandrakanth @ChandrakanthMv]

Alcohol increases breast cancer risk — and it’s dose-dependent 🍷
+13% (light) → +52% (heavy)
Stronger in HR+ disease.
After diagnosis? No clear rise in recurrence.
Less alcohol = lower risk.
#MVOnco #BreastCancer #Oncology #CancerPrevention

[Lamia__Ker🇩🇿💫 @zhrlmdn20529137]

هذا المصري بردلي قلبي في المراركة يعطيه الصحة 👏🏾.
#أنا_مع_بلادي
#طرد_المراركة_مطلب_شعبي_وطني